ArticleDiscover oncology2025
Risk factors and prognostic nomogram for distant metastasis in patients with PTMC.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
There is controversy regarding treatment selection for papillary thyroid microcarcinoma (PTMC), and a prediction model for PTMC distant metastasis (DM) is critically needed to guide treatment planning. Therefore, we study retrospectively analyzed the Surveillance, Epidemiology, and End Results (SEER) database to explore the risk factors and construct a novel DM prediction nomogram for DM in patients with PTMC (PTMC-DM). Data of patients with PTMC, covering 2004 to 2015, were gathered from the SEER database. Cox proportional hazards regression, Kaplan Meier methods and log-rank tests were conducted to identify the independent prognostic factors for predicting DM. These significant prognostic factors were used for the development of an DM prediction nomogram. Totally 27,933 PTMC samples gathered from the SEER database, 72 patients (0.26%) had PTMC-DM at the time of diagnosis and 107 (0.38%) died from thyroid disease, were divided into training cohort and validation cohort (score construction and internal validation) at random. Multivariate Cox regression analysis showed that T stage, N stage, gender, and age were independent risk factors for DM in PTMC patients. The prognostic nomogram we constructed was also for DM. Additionally, calibration curves and decision curve analysis (DCA) curves revealed that the nomogram has excellent clinical utility. The prognostic characteristics of PTMC-DM were systematically reviewed. Our constructed nomogram predicts survival to assist clinicians in making individualized treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.